209 related articles for article (PubMed ID: 23977117)
41. Distinct genetic alterations in pediatric glioblastomas.
Byeon SJ; Myung JK; Kim SH; Kim SK; Phi JH; Park SH
Childs Nerv Syst; 2012 Jul; 28(7):1025-32. PubMed ID: 22570167
[TBL] [Abstract][Full Text] [Related]
42. Measurements of diagnostic examination performance and correlation analysis using microvascular leakage, cerebral blood volume, and blood flow derived from 3T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in glial tumor grading.
Server A; Graff BA; Orheim TE; Schellhorn T; Josefsen R; Gadmar ØB; Nakstad PH
Neuroradiology; 2011 Jun; 53(6):435-47. PubMed ID: 20857284
[TBL] [Abstract][Full Text] [Related]
43. Machine learning-based radiomic, clinical and semantic feature analysis for predicting overall survival and MGMT promoter methylation status in patients with glioblastoma.
Lu Y; Patel M; Natarajan K; Ughratdar I; Sanghera P; Jena R; Watts C; Sawlani V
Magn Reson Imaging; 2020 Dec; 74():161-170. PubMed ID: 32980505
[TBL] [Abstract][Full Text] [Related]
44. O
Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
[TBL] [Abstract][Full Text] [Related]
45. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
[TBL] [Abstract][Full Text] [Related]
46. Correlation between quantified promoter methylation and enzymatic activity of O6-methylguanine-DNA methyltransferase in glioblastomas.
Kishida Y; Natsume A; Toda H; Toi Y; Motomura K; Koyama H; Matsuda K; Nakayama O; Sato M; Suzuki M; Kondo Y; Wakabayashi T
Tumour Biol; 2012 Apr; 33(2):373-81. PubMed ID: 22274924
[TBL] [Abstract][Full Text] [Related]
47. Comparison of BOLD cerebrovascular reactivity mapping and DSC MR perfusion imaging for prediction of neurovascular uncoupling potential in brain tumors.
Pillai JJ; Zacà D
Technol Cancer Res Treat; 2012 Aug; 11(4):361-74. PubMed ID: 22376130
[TBL] [Abstract][Full Text] [Related]
48. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
49. Antiangiogenic Effect of Bevacizumab: Application of Arterial Spin-Labeling Perfusion MR Imaging in a Rat Glioblastoma Model.
Yun TJ; Cho HR; Choi SH; Kim H; Won JK; Park SW; Kim JH; Sohn CH; Han MH
AJNR Am J Neuroradiol; 2016 Sep; 37(9):1650-6. PubMed ID: 27173366
[TBL] [Abstract][Full Text] [Related]
50. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
[TBL] [Abstract][Full Text] [Related]
51. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging.
Drabycz S; Roldán G; de Robles P; Adler D; McIntyre JB; Magliocco AM; Cairncross JG; Mitchell JR
Neuroimage; 2010 Jan; 49(2):1398-405. PubMed ID: 19796694
[TBL] [Abstract][Full Text] [Related]
52. Identification of a candidate biomarker from perfusion MRI to anticipate glioblastoma progression after chemoradiation.
Khalifa J; Tensaouti F; Chaltiel L; Lotterie JA; Catalaa I; Sunyach MP; Ibarrola D; Noël G; Truc G; Walker P; Magné N; Charissoux M; Ken S; Peran P; Berry I; Moyal EC; Laprie A
Eur Radiol; 2016 Nov; 26(11):4194-4203. PubMed ID: 26843012
[TBL] [Abstract][Full Text] [Related]
53. Longitudinal, leakage corrected and uncorrected rCBV during the first-line treatment of glioblastoma: a prospective study.
Steidl E; Müller M; Müller A; Herrlinger U; Hattingen E
J Neurooncol; 2019 Sep; 144(2):409-417. PubMed ID: 31321614
[TBL] [Abstract][Full Text] [Related]
54. Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma.
Xi YB; Guo F; Xu ZL; Li C; Wei W; Tian P; Liu TT; Liu L; Chen G; Ye J; Cheng G; Cui LB; Zhang HJ; Qin W; Yin H
J Magn Reson Imaging; 2018 May; 47(5):1380-1387. PubMed ID: 28926163
[TBL] [Abstract][Full Text] [Related]
55. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
[TBL] [Abstract][Full Text] [Related]
56. The Value of 5-Aminolevulinic Acid in Low-grade Gliomas and High-grade Gliomas Lacking Glioblastoma Imaging Features: An Analysis Based on Fluorescence, Magnetic Resonance Imaging, 18F-Fluoroethyl Tyrosine Positron Emission Tomography, and Tumor Molecular Factors.
Jaber M; Wölfer J; Ewelt C; Holling M; Hasselblatt M; Niederstadt T; Zoubi T; Weckesser M; Stummer W
Neurosurgery; 2016 Mar; 78(3):401-11; discussion 411. PubMed ID: 26366972
[TBL] [Abstract][Full Text] [Related]
57. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
58. Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres.
Sciuscio D; Diserens AC; van Dommelen K; Martinet D; Jones G; Janzer RC; Pollo C; Hamou MF; Kaina B; Stupp R; Levivier M; Hegi ME
Clin Cancer Res; 2011 Jan; 17(2):255-66. PubMed ID: 21097691
[TBL] [Abstract][Full Text] [Related]
59. Automatic Prediction of MGMT Status in Glioblastoma via Deep Learning-Based MR Image Analysis.
Chen X; Zeng M; Tong Y; Zhang T; Fu Y; Li H; Zhang Z; Cheng Z; Xu X; Yang R; Liu Z; Wei X; Jiang X
Biomed Res Int; 2020; 2020():9258649. PubMed ID: 33029531
[TBL] [Abstract][Full Text] [Related]
60. Radiological model based on the standard magnetic resonance sequences for detecting methylguanine methyltransferase methylation in glioma using texture analysis.
Huang WY; Wen LH; Wu G; Pang PP; Ogbuji R; Zhang CC; Chen F; Zhao JN
Cancer Sci; 2021 Jul; 112(7):2835-2844. PubMed ID: 33932065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
